Vistagen Therapeutics Inc., of South San Francisco, reported preclinical data for AV-101, an oral N-methyl-D-aspartate receptor glycine B antagonist, showing the drug increased neurogenesis, defined by an increased number of cells containing Ki67, in the hippocampus of rodents following oral daily dosing for 14 to 16 days. The data will be presented at an upcoming psychiatry conference.